Shane Barton - 18 Dec 2024 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Reporting relationship: Principal Accounting Officer
Issuer ticker: BIOA
Reported as of: 18 Dec 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Dec 2024, 16:04:55 UTC
Prior SEC filing: 10 Mar 2025
Next SEC filing: 20 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Dov A. Goldstein as attorney-in-fact

Key filing fact

Shane Barton filed Form 4 for BioAge Labs, Inc. (BIOA) on 20 Dec 2024.

Key facts

This page summarizes Shane Barton's Form 4 filing for BioAge Labs, Inc. (BIOA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Dec 2024, 16:04.

Change

Previous filing in this sequence was filed on 10 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 18 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $4.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 26, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.